Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive's Stephen Gunnion about the company's €12 million fundraising through an oversubscribed share placing. Originally set at €10 million, strong investor confidence in Faron’s programs, particularly in bexmarilimab, led to an increase in the raise.
Jalkanen emphasised that this funding comes at a pivotal time for the company. He highlighted the completion of patient enrollment in the Phase II BEXMAB trial for relapsed refractory myelodysplastic syndromes (MDS), a form of leukemia with a poor prognosis. The Phase II readout, expected in April, will be a major milestone, with early data showing an increase in survival from 5-6 months to 13.4 months and an 80% response rate.
Beyond the readout, Jalkanen outlined key 2025 milestones, including presentations at major medical conferences, discussions with the FDA, and further business developments. He stated, “We are well funded beyond this, and we are geared for success.”
For more insights into Faron Pharmaceuticals' progress, watch the full interview. Don't forget to like, subscribe, and turn on notifications for Proactive's latest updates.
#FaronPharmaceuticals #Bexmarilimab #CancerResearch #BiotechInvesting #PharmaNews #ClinicalTrials #BiotechStocks #FDA #Investing #Healthcare
